Form 4: Vaxcyte Director Carlos Paya Receives Significant Equity Compensation Grant

Vaxcyte, Inc. Director Carlos V. Paya was granted 3,041 restricted stock units and 15,372 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Carlos V. Paya, a Director of Vaxcyte, Inc. (PCVX), reported the acquisition of equity securities on June 12, 2025.
• Mr. Paya was granted 3,041 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• Each RSU represents the contingent right to receive one share of Vaxcyte's Common Stock.
• These RSUs are scheduled to fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on Mr. Paya's continuous service.
• Additionally, Mr. Paya was granted 15,372 stock options with an exercise price of $34.46 per share.
• The stock options will vest monthly and fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, also subject to continuous service.
• The stock options have an expiration date of June 12, 2035.
• Following these transactions, Mr. Paya directly beneficially owns 4,591 shares of Common Stock and 15,372 stock options.
• An additional 5,625 shares of Common Stock are indirectly beneficially owned by a Family Trust.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects routine, incentivizing compensation for a director, aligning their interests with shareholders. There are no negative implications from this specific filing.

Positives

• The grant of equity compensation (Restricted Stock Units and Stock Options) to a director aligns the director's financial interests with those of the shareholders.
• The compensation structure, with its vesting schedules tied to continuous service, incentivizes long-term commitment and performance from the director.

Negatives

• No specific negative aspects are directly stated or implied by this routine insider compensation filing.

Risks

• None directly stated in this filing, as Form 4 primarily reports ownership changes, not company-specific risks. The value of the granted equity is inherently subject to market fluctuations.

Future Outlook

The future outlook for the granted equity compensation is tied to the vesting schedule, with full vesting expected by June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on the director's continuous service. The stock options have a long-term expiration date of June 12, 2035, providing a long window for potential exercise.

Industry Context

The grant of Restricted Stock Units and Stock Options to a director is a standard practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key personnel. This form of equity compensation aligns the interests of the director with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• This type of equity grant is a common component of director compensation packages across various industries, including biotechnology.
• While specific grant sizes vary by company size, stage, and individual role, the use of RSUs and stock options with performance or time-based vesting is a widely adopted mechanism to incentivize long-term value creation.
• No specific comparable companies or projects are mentioned in this filing to allow for a direct quantitative comparison of the grant size.

Related Party Transactions

• The indirect beneficial ownership of 5,625 shares of Common Stock by a Family Trust is noted, indicating a related party holding.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• Continued service of Carlos V. Paya as a Director of Vaxcyte, Inc.
• Vesting of the 3,041 Restricted Stock Units on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders.
• Monthly vesting of the 15,372 Stock Options, with full vesting on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders.
• Potential exercise of stock options by June 12, 2035.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Beneficial Ownership